Pregled bibliografske jedinice broj: 549543
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR // The world journal of biological psychiatry, 12 (2011), 7; 528-538 doi:10.3109/15622975.2011.559270 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 549543 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR
Autori
Strohmaier, J. ; Wüst, S. ; Uher, R. ; Henigsberg, Neven ; Mors, O. ; Hauser, J. ; Souery, D. ; Zobel, A. ; Dernovsek, M.Z. ; Streit, F. ; Schmäl, C. ; Kozel, D. ; Placentino, A. ; Farmer, A. ; McGuffin, P. ; Aitchison, K.J. ; Rietschel, M.
Izvornik
The world journal of biological psychiatry (1562-2975) 12
(2011), 7;
528-538
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
sexual dysfunction; 5-HTTLPR; selective serotonin uptake inhibitors; escitalopram; nortriptyline
Sažetak
Sexual dysfunction (SD) is a frequently reported side-effect of antidepressant treatment, particularly of selective serotonin reuptake inhibitors (SSRIs). In the multicentre clinical and pharmacogenetic GENDEP study (Genome-based Therapeutic Drugs for Depression), the effect of the serotonin transporter gene promoter polymorphism 5-HTTLPR on sexual function was investigated during treatment with escitalopram (SSRI) and nortriptyline (tricyclic antidepressant). A total of 494 subjects with an episode of DSM-IV major depression were randomly assigned to treatment with escitalopram or nortriptyline. Over 12 weeks, depressive symptoms and SD were measured weekly with the Montgomery–Asberg Depression Rating Scale, the Antidepressant Side-Effect Checklist, the UKU Side Effect Rating Scale, and the Sexual Functioning Questionnaire. The incidence of reported SD after 12 weeks of treatment was relatively low, and did not differ significantly between antidepressants (14.9% escitalopram, 19.7% nortriptyline). There was no significant interaction between the 5-HTTLPR and antidepressant on SD. Improvement in depressive symptoms and younger age were both associated with lower SD. The effect of age on SD may have been moderated by the 5-HTTLPR. In GENDEP, rates of reported SD during treatment were lower than those described in previous reports. There was no apparent effect of the 5-HTTLPR on the observed decline in SD.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081870-1880 - 1H-MRS promjene u predviđanju terapijskog odgovora, relapsa i povrata depresije (Henigsberg, Neven, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Neven Henigsberg
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE